Can a cheap, common drug ease the crushing fatigue of long COVID?
Yes. In this trial of 399 adults with long COVID fatigue, low-dose fluvoxamine reduced fatigue more than a placebo, and the benefit held up over three months. People on the drug were nearly 50% more likely to call their fatigue minimal after 30 days.
Long COVID fatigue is one of the hardest problems in medicine right now. Millions of people feel wiped out for months after a COVID infection, and almost nothing has been proven to help. This study is one of the first solid trials to point to a real treatment, and it is a drug that is already cheap and easy to find.
What is fluvoxamine and why test it?
Fluvoxamine is an older medicine usually prescribed for depression and obsessive-compulsive disorder. It belongs to a group of drugs called SSRIs. Researchers became interested in it for COVID because it also seems to calm inflammation, the body’s overactive alarm system. Since long COVID fatigue may be driven partly by lingering inflammation, the idea was that fluvoxamine might quiet that fire and give people their energy back.
The trial also tested metformin, a common diabetes drug that has been studied for many other conditions. Both drugs are inexpensive and widely available, which is a big part of why this research matters.
What the data show
The results for fluvoxamine were clear. Adults took 100 mg twice a day, and by day 60 they reported significantly less fatigue than people taking a placebo. That improvement did not fade. It was still there at day 90, which suggests a lasting effect rather than a short bump.
The size of the change mattered too. After just 30 days, people on fluvoxamine were nearly 50% more likely than the placebo group to rate their fatigue as minimal. In a condition where most days feel like wading through mud, that shift toward normal is meaningful.
Safety looked reassuring as well. Side effects were actually less common with fluvoxamine, at 20.0%, than with placebo, at 29.7%. It is unusual for an active drug to cause fewer problems than a sugar pill, and it suggests the medicine was well tolerated at this low dose.
Metformin was a different story. It showed no benefit for people who already had established long COVID fatigue, and that part of the trial was stopped early for futility, meaning it was clear more testing would not change the answer.
Dr. Kumar’s Take
I find this trial genuinely important, and I say that carefully because I try not to oversell early results. What grabs my attention is the combination of things here. The study was randomized and placebo-controlled, which is the gold standard. The benefit lasted to day 90 instead of vanishing. And the drug is one I can already prescribe, that costs very little, and that has decades of safety history behind it.
I am also glad they reported the metformin failure honestly. Negative results save patients from wasting money and hope on something that does not work. For a condition that has left so many people without options, having one proven, affordable tool feels like real progress. I would still want to see larger and longer studies before calling this a cure, but this is the kind of finding that can change how I counsel patients.
Who might benefit most
This trial focused on adults who had been dragging through fatigue for at least 90 days after a confirmed COVID infection. These were not people with a mild, passing tiredness. They had persistent, disabling fatigue, the kind that disrupts work and daily life. That is exactly the group with the fewest good options today, which makes the signal here more encouraging.
Safety, limits, and caveats
There are honest limits to keep in mind. Fluvoxamine is an SSRI, so it can interact with other medicines and is not right for everyone. Anyone considering it should talk with a doctor who knows their full history. This was also a single trial, and long COVID can look different from person to person, so results may not apply to every case. Finally, the study looked at fatigue specifically, not every symptom of long COVID. Still, the careful design and lasting benefit give me more confidence than usual in an early result.
Practical Takeaways
- If you have long COVID fatigue that has lasted months, ask your doctor whether low-dose fluvoxamine might be reasonable to try, since this trial used 100 mg twice a day.
- Do not start or stop any SSRI on your own, because these drugs need proper dosing and can interact with other medicines you take.
- Set realistic expectations, as the benefit in this study built up over 30 to 60 days rather than working overnight.
- Skip metformin for this purpose, since the trial found it gave no help for fatigue that was already established.
Related Studies and Research
- Single-dose psilocybin vs placebo: the first double-blind depression trial
- Mindfulness-based cognitive therapy for depression: dose-response, inflammation, and BDNF
- The long-term oxygen treatment trial and its health benefits
- Single-dose psilocybin shows rapid, sustained antidepressant effects
FAQs
How long does fluvoxamine take to help long COVID fatigue?
In this trial the benefit was measured at day 60, so it was not an instant fix. People took the drug twice a day and the improvement built up over the first month or two. The effect then held steady through day 90, which suggests patience is needed and the medicine works gradually. If you try it, plan on giving it several weeks before judging whether it helps.
Is fluvoxamine safe for people who are not depressed?
Fluvoxamine is an antidepressant, but in this study it was used for its effects on inflammation, not mood. Notably, side effects were less common with the drug than with placebo, which points to good tolerance at the low dose used. That said, SSRIs can interact with other medicines and are not appropriate for everyone. A doctor should review your health history and current prescriptions before you start.
Why did metformin fail when fluvoxamine worked?
The two drugs work in very different ways in the body, so it is not surprising they had different results. In this trial, metformin offered no benefit for fatigue that was already established, and that arm was stopped early for futility. Fluvoxamine, by contrast, may help calm the inflammation thought to drive long COVID fatigue. The honest reporting of metformin’s failure is a strength of the study, not a weakness.
Bottom Line
For a condition that has frustrated patients and doctors alike, this trial offers a rare piece of good news. Low-dose fluvoxamine reduced long COVID fatigue compared with placebo, the benefit lasted three months, and side effects were actually fewer than with a sugar pill. Metformin did not help. Because fluvoxamine is cheap, familiar, and easy to find, this is one of the first practical, proven options for people whose lives have been upended by lingering fatigue. Larger studies are still needed, but this is a real step forward.
